Compare Honeywell International Inc (HON) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs Merck & Co., Inc. — how do they compare? Honeywell International Inc trades at $232.62 (market cap $72.93B), while Merck & Co., Inc. trades at $132.88 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 4.4× Honeywell International Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| HON | MRK | |
|---|---|---|
Market Cap | $72.93B | $321.77B |
Sector | Industrials | Health |
52-Week High | $248.79 | $131.84 |
52-Week Low | $188.14 | $77.60 |
Enterprise Value | $97.73B | $368.53B |
Dividend Yield | 1.22% | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International Inc. (HON) trades at $232.35, down 4.36% amid disappointing growth guidance from a recent investor event. The stock exhibits bearish technical signals with support near $225, while fundamentals remain solid with a low P/E of 8.85 and strong profitability margins. Recent corporate actions include dividend payments and business divestitures, positioning the company as a focused automation play.
The outlook is mixed: attractive valuation and consistent earnings beats support upside toward the $320.54 consensus target, but near-term sentiment is pressured by growth concerns and technical weakness. Key risks include execution of the portfolio transformation and macroeconomic headwinds affecting industrial demand.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
